Cargando…
iPSC Therapy for Myocardial Infarction in Large Animal Models: Land of Hope and Dreams
Myocardial infarction is the main driver of heart failure due to ischemia and subsequent cell death, and cell-based strategies have emerged as promising therapeutic methods to replace dead tissue in cardiovascular diseases. Research in this field has been dramatically advanced by the development of...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8698445/ https://www.ncbi.nlm.nih.gov/pubmed/34944652 http://dx.doi.org/10.3390/biomedicines9121836 |
_version_ | 1784620281388597248 |
---|---|
author | Martínez-Falguera, Daina Iborra-Egea, Oriol Gálvez-Montón, Carolina |
author_facet | Martínez-Falguera, Daina Iborra-Egea, Oriol Gálvez-Montón, Carolina |
author_sort | Martínez-Falguera, Daina |
collection | PubMed |
description | Myocardial infarction is the main driver of heart failure due to ischemia and subsequent cell death, and cell-based strategies have emerged as promising therapeutic methods to replace dead tissue in cardiovascular diseases. Research in this field has been dramatically advanced by the development of laboratory-induced pluripotent stem cells (iPSCs) that harbor the capability to become any cell type. Like other experimental strategies, stem cell therapy must meet multiple requirements before reaching the clinical trial phase, and in vivo models are indispensable for ensuring the safety of such novel therapies. Specifically, translational studies in large animal models are necessary to fully evaluate the therapeutic potential of this approach; to empirically determine the optimal combination of cell types, supplementary factors, and delivery methods to maximize efficacy; and to stringently assess safety. In the present review, we summarize the main strategies employed to generate iPSCs and differentiate them into cardiomyocytes in large animal species; the most critical differences between using small versus large animal models for cardiovascular studies; and the strategies that have been pursued regarding implanted cells’ stage of differentiation, origin, and technical application. |
format | Online Article Text |
id | pubmed-8698445 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-86984452021-12-24 iPSC Therapy for Myocardial Infarction in Large Animal Models: Land of Hope and Dreams Martínez-Falguera, Daina Iborra-Egea, Oriol Gálvez-Montón, Carolina Biomedicines Review Myocardial infarction is the main driver of heart failure due to ischemia and subsequent cell death, and cell-based strategies have emerged as promising therapeutic methods to replace dead tissue in cardiovascular diseases. Research in this field has been dramatically advanced by the development of laboratory-induced pluripotent stem cells (iPSCs) that harbor the capability to become any cell type. Like other experimental strategies, stem cell therapy must meet multiple requirements before reaching the clinical trial phase, and in vivo models are indispensable for ensuring the safety of such novel therapies. Specifically, translational studies in large animal models are necessary to fully evaluate the therapeutic potential of this approach; to empirically determine the optimal combination of cell types, supplementary factors, and delivery methods to maximize efficacy; and to stringently assess safety. In the present review, we summarize the main strategies employed to generate iPSCs and differentiate them into cardiomyocytes in large animal species; the most critical differences between using small versus large animal models for cardiovascular studies; and the strategies that have been pursued regarding implanted cells’ stage of differentiation, origin, and technical application. MDPI 2021-12-05 /pmc/articles/PMC8698445/ /pubmed/34944652 http://dx.doi.org/10.3390/biomedicines9121836 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Martínez-Falguera, Daina Iborra-Egea, Oriol Gálvez-Montón, Carolina iPSC Therapy for Myocardial Infarction in Large Animal Models: Land of Hope and Dreams |
title | iPSC Therapy for Myocardial Infarction in Large Animal Models: Land of Hope and Dreams |
title_full | iPSC Therapy for Myocardial Infarction in Large Animal Models: Land of Hope and Dreams |
title_fullStr | iPSC Therapy for Myocardial Infarction in Large Animal Models: Land of Hope and Dreams |
title_full_unstemmed | iPSC Therapy for Myocardial Infarction in Large Animal Models: Land of Hope and Dreams |
title_short | iPSC Therapy for Myocardial Infarction in Large Animal Models: Land of Hope and Dreams |
title_sort | ipsc therapy for myocardial infarction in large animal models: land of hope and dreams |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8698445/ https://www.ncbi.nlm.nih.gov/pubmed/34944652 http://dx.doi.org/10.3390/biomedicines9121836 |
work_keys_str_mv | AT martinezfalgueradaina ipsctherapyformyocardialinfarctioninlargeanimalmodelslandofhopeanddreams AT iborraegeaoriol ipsctherapyformyocardialinfarctioninlargeanimalmodelslandofhopeanddreams AT galvezmontoncarolina ipsctherapyformyocardialinfarctioninlargeanimalmodelslandofhopeanddreams |